Universitätsklinikum Tübingen
Tübingen, Germany
29 recruiting
Showing 1–20 of 57 trials
Recruiting
Not Applicable
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Atrial FibrillationIschemic Stroke
Insel Gruppe AG, University Hospital Bern482 enrolled29 locationsNCT05976685
Recruiting
Phase 3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Chronic Kidney Disease
Boehringer Ingelheim120 enrolled102 locationsNCT07107945
Recruiting
Phase 2Phase 3
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma
Global Coalition for Adaptive Research2,250 enrolled63 locationsNCT03970447
Recruiting
Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled373 locationsNCT06238622
Recruiting
Phase 3
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Pyoderma Gangrenosum
Boehringer Ingelheim90 enrolled96 locationsNCT06624670
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 2
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
HER2 Positive Early Breast Cancer
West German Study Group702 enrolled44 locationsNCT05704829
Recruiting
Phase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.160 enrolled138 locationsNCT05667142
Recruiting
Not Applicable
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Deep Venous ThrombosisVenous ThromboembolismPost Thrombotic Syndrome
Inari Medical300 enrolled64 locationsNCT05701917
Recruiting
Phase 1
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Neuroendocrine Neoplasms
Boehringer Ingelheim55 enrolled20 locationsNCT06132113
Recruiting
Phase 1
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderBorderline Personality Disorder
Boehringer Ingelheim96 enrolled9 locationsNCT07001475
Recruiting
Phase 1Phase 2
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Advanced Solid Tumor
BioNTech SE980 enrolled64 locationsNCT07070232
Recruiting
Not Applicable
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
Treatment Resistant DepressionPersistent Depressive Disorder
University of Greifswald396 enrolled8 locationsNCT04996433
Recruiting
Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection
VEXAS Syndrome
Technische Universität Dresden500 enrolled17 locationsNCT06377462
Recruiting
Phase 1
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Solid Tumors
Boehringer Ingelheim190 enrolled40 locationsNCT05155332
Recruiting
Phase 1
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Triple-Negative Breast CancerColorectal, CancerSarcoma+5 more
Valo Therapeutics Oy15 enrolled7 locationsNCT05492682
Recruiting
Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study
Chronic Limb Threatening Ischemia
Cardiovascular and Interventional Radiological Society of Europe400 enrolled39 locationsNCT06149650
Recruiting
Phase 3
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Alpha1-Antitrypsin Deficiency
Takeda160 enrolled89 locationsNCT05677971
Recruiting
Treatment Guided by Comprehensive Genome and Transcriptome Analysis Versus Standard of Care in Advanced Rare Cancers
Rare Cancer
German Cancer Research Center946 enrolled16 locationsNCT06855134
Recruiting
Phase 3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Uveal Melanoma
IDEAYA Biosciences520 enrolled94 locationsNCT07015190